Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02491073 · ClinicalTrials.gov registry record
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
A clinical trial, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- 71
- Enrollment target
NCT02491073 is a clinical trial that has completed, run by Sumitomo Pharma America. The registered enrollment target is 71 participants.
The verdict
NCT02491073 has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if the blood tests used to measure free thyroid hormone levels are affected by a drug called eslicarbazepine acetate. To determine if eslicarbazepine acetate interferes with these blood tests, blood samples will be analysed so that researchers can compare different types of lab tests that measure these thyroid hormones. Half of the people who participate in this study will already be taking eslicarbazepine acetate either as a study drug or as a prescription (Part 1) and the other half will be people who do not take eslicarbazepine acetate (Part 2).
Interventions
- OTHER blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02491073
The ClinicalTrials.gov registry entry for NCT02491073 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which blood draw is the first listed.
NCT02491073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02491073 about?
NCT02491073 is a clinical study titled "Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)". The purpose of this research study is to determine if the blood tests used to measure free thyroid hormone levels are affected by a drug called eslicarbazepine acetate. To determine if eslicarbazepine acetate interferes with these blood tests, blood samples will be analysed so that researchers can c...
What is the current status of trial NCT02491073?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2015-09. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02491073?
The interventions under investigation include: blood draw (OTHER).
Who is sponsoring clinical trial NCT02491073?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.